Fusion Pharmaceuticals Analysis
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
Fusion Pharmaceuticals is overvalued with Real Value of 3.52 and Hype Value of 3.75. The main objective of Fusion Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Fusion Pharmaceuticals is worth, separate from its market price. There are two main types of Fusion Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Fusion Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Fusion Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Fusion Stock trading window is adjusted to America/New York timezone.
Fusion |
Fusion Stock Analysis Notes
About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.4. Fusion Pharmaceuticals had not issued any dividends in recent years. Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals is traded on NASDAQ Exchange in the United States. To learn more about Fusion Pharmaceuticals call John Valliant at 289 799 0891 or check out https://www.fusionpharma.com.Fusion Pharmaceuticals Investment Alerts
| Fusion Pharmaceuticals is not yet fully synchronised with the market data | |
| Fusion Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.07 M. Net Loss for the year was (94.9 M) with loss before overhead, payroll, taxes, and interest of (57.43 M). | |
| Fusion Pharmaceuticals currently holds about 198.42 M in cash with (81.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors |
Fusion Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Fusion Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Fusion Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.83 B.Fusion Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fusion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fusion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fusion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Christopher Leamon over six months ago Acquisition by Christopher Leamon of 106100 shares of Fusion PharmaceuticalsI at 8.44 subject to Rule 16b-3 | ||
Mohit Rawat over a year ago Acquisition by Mohit Rawat of 12843 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 | ||
Meek David D over a year ago Acquisition by Meek David D of 34000 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 | ||
Khuong Chau Quang over a year ago Acquisition by Khuong Chau Quang of 17000 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 |
Fusion Pharmaceuticals Outstanding Bonds
Fusion Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fusion Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fusion bonds can be classified according to their maturity, which is the date when Fusion Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Fusion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fusion Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fusion shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Fusion Pharmaceuticals. By using and applying Fusion Stock analysis, traders can create a robust methodology for identifying Fusion entry and exit points for their positions.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fusion Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |